Recordati Overview
- Founded
-
1926

- Status
-
Public
- Employees
-
4,300

- Stock Symbol
-
REC

- Investments
-
21
- Share Price
-
$43.90
- (As of Friday Closing)
Recordati General Information
Description
Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth strategy. The vast majority of the company's revenue is generated in Italy, followed by France and Germany. Recordati reports two operating segments: Specialty and Primary care and Rare diseases. The bulk of the company's profit is derived from its specialty and primary care segment, which includes the production of active ingredients.
Contact Information
- Via Matteo Civitali, 1
- 20148 Milan
- Italy
Recordati Stock Performance
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$43.90 | $44.03 | $33.51 - $56.15 | $9B | 205M | 208K | $1.74 |
Recordati Financials Summary
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 9,134,386 | 14,008,795 | 12,480,515 | 9,142,629 |
Revenue | 1,949,048 | 1,868,119 | 1,651,582 | 1,658,847 |
EBITDA | 607,794 | 683,787 | 646,138 | 601,557 |
Net Income | 358,165 | 456,327 | 404,651 | 412,879 |
Total Assets | 3,909,785 | 3,188,559 | 3,335,245 | 3,146,485 |
Total Debt | 1,671,232 | 1,123,379 | 1,305,067 | 1,232,809 |
Recordati Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Recordati Comparisons
Industry
Financing
Details
Recordati Competitors (55)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Cipla | Corporation | Mumbai, India | 00000 | 00000000 | ||
000000000 000000 | Corporation | Daix, France | 000 | 00000 | 00000000 | 00000 |
0000000000 0000000 | Corporation | Ingelheim am Rhein, Germany | 00000 | |||
00000 000000000000 | Private Equity-Backed | Ahmedabad, India | 00000 | 000.00 | 00000000000 | 000.00 |
00000000 000000 | Corporation | Tokyo, Japan | 00000 | 00000000 |
Recordati Patents
Recordati Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20200397728-A1 | Pharmaceutical formulation for carglumic acid | Inactive | 30-May-2019 | 0000000000 | |
US-20220071938-A1 | Treatment of hyperammonemia in patients with renal insufficiency | Inactive | 22-May-2019 | 0000000000 | |
US-20220040129-A1 | Treatment of hyperammonemia in patients with renal insufficiency | Inactive | 22-May-2019 | 0000000000 | |
EP-3972580-A1 | Treatment of hyperammonemia in patients with renal insufficiency | Pending | 22-May-2019 | 0000000000 | |
US-20200368192-A1 | Treatment of hyperammonemia in patients with renal insufficiency | Inactive | 22-May-2019 | A61K31/197 |
Recordati Executive Team (10)
Recordati Board Members (10)
Name | Representing | Role | Since |
---|---|---|---|
0000000 000000000 | Self | Board Member | 000 0000 |
000000 000000000 | Recordati | Board Member | 000 0000 |
00000 0000000 | Recordati | Board Member & General Manager | 000 0000 |
00000 00000 | Self | Board Member & Vice Chairman | 000 0000 |
000 00000000 | Self | Board Member | 000 0000 |
Recordati Signals
Recordati Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Recordati Investments & Acquisitions (21)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
0000 000000 | 16-Mar-2022 | 0000000000 | 00000 | Pharmaceuticals | 00000000 |
00000000 (000 | 23-Oct-2019 | 000000000 | 00000 | Buildings and Property | 0000000 0 |
000000000 | 31-Dec-2018 | 0000000000 | 000.00 | Pharmaceuticals | 000000 00 |
0000000 00000 | 11-Jun-2018 | 0000000000 | 000.00 | Food Products | 0000000 0 |
Three Bayer Consumer Health Brands (Ransipeg, TransipegLib and Colopeg) | 18-Dec-2017 | Corporate Asset Purchase | 000.00 | Buildings and Property | 000000 00 |
Recordati Subsidiaries (6)
Company Name | Industry | Location | Founded |
---|---|---|---|
EUSA Pharma | Pharmaceuticals | Hemel Hempstead, United Kingdom | 2006 |
0000000 00000 | Food Products | Milan, Italy | 0000 |
000000000 | Pharmaceuticals | Boulogne, France | 0000 |
000000 000000 | Pharmaceuticals | Puteaux, France | 0000 |
00000 00000 000000 | Pharmaceuticals | Madrid, Spain | 0000 |
Recordati ESG
Risk Overview
Risk Rating
Updated September, 30, 2022
28.23 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,638
Rank
Percentile

Pharmaceuticals
Industry
00 of 1,008
Rank
Percentile

Pharmaceuticals
Subindustry
00 of 473
Rank
Percentile

Recordati Exits (1)
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
00000000000000 | 01-Jan-1986 | 000000000000000000 | Completed |
|